Medicus Pharma partners With Reliant AI to advance AI-driven clinical trial analytics

Medicus Pharma Chief Medical Officer Dr. Faisel Mehmud joined Steve Darling from Proactive to announce that the company has entered into a non-binding letter of intent with Reliant AI, a decision-intelligence company specializing in generative artificial intelligence for the life sciences. The proposed collaboration is focused on developing an AI-powered data analytics platform designed to enhance clinical trial execution through advanced, data-driven insights. Reliant AI is a privately held company founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, alongside life sciences expert Richard Schlegel. The company combines state-of-the-art machine learning techniques with deep biomedical expertise to automate data-intensive workflows across the life sciences, ranging from systematic literature reviews to commercial success prediction. Its platform is designed to enable biopharma teams to make faster, more informed, evidence-based decisions throughout the research and development lifecycle. Dr. Mehmud explained that the proposed platform would integrate Reliant AI’s proprietary generative AI technology with Medicus’ clinical, operational, and internal datasets. The goal is to strengthen data-driven decision-making across Medicus’ clinical pipeline, with a particular focus on improving trial efficiency. Key anticipated capabilities include dynamic clinical-site selection, enhanced patient stratification, and more accurate enrollment forecasting. The initial phase of the collaboration is expected to focus on dynamic site selection supported by targeted patient-stratification analyses for an upcoming Teverelix clinical study, which is planned to begin in 2026. Subject to the execution of definitive agreements, Medicus expects the data analytics platform to be deployed initially in support of a Medicus-sponsored study during the Q2 to Q4 2026 period. There is also potential for the platform to be expanded to support a larger, late-stage clinical study planned for 2028, potentially in collaboration with a development or commercial partner. Medicus Pharma is currently advancing its SKNJCT-003 Phase 2 clinical study, which is being conducted across nine clinical sites in the United States. The study, which began randomizing patients in August 2024, is a randomized, double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating a non-invasive treatment for basal cell carcinoma of the skin. The study uses Medicus’ novel, patent-protected, dissolvable doxorubicin-containing microneedle array (D-MNA) technology, highlighting the company’s broader commitment to innovation in both therapeutic development and clinical execution. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews